Comparison of demographic data among the PDD, DLB and AD groups.

<p>Comparison of demographic data among the PDD, DLB and AD groups.</p

Multivariate risk estimates (ORs) for all patients with NPI ≥ 21 (N = 440, 50.3%) compared to those with NPI ≤ 20 (N = 435, 49.7%).

<p>Multivariate risk estimates (ORs) for all patients with NPI ≥ 21 (N = 440, 50.3%) compared to those with NPI ≤ 20 (N = 435, 49.7%).</p

Comparison of composite score (severity x frequency) of each item in the NPI among the PDD, DLB and AD groups adjusted for gender and use of antipsychotics.

<p>Comparison of composite score (severity x frequency) of each item in the NPI among the PDD, DLB and AD groups adjusted for gender and use of antipsychotics.</p

Demographic and clinical characteristics between comparison and MDD groups.

<p>BMI: body mass index.</p><p>TCA: tricyclic antidepressant.</p><p>SSRI: selective serotonin reuptake inhibitor.</p><p>SNRI: selective serotonin-norepinephrine inhibitor.</p><p>NaSSA: noradrenergic and specific serotonergic antidepressant.</p><p>BZDs: benzodiazepines.</p><p>IQR: interquartile range.</p><p>Demographic and clinical characteristics between comparison and MDD groups.</p

A 48-Week, Multicenter, Open-Label, Observational Study, Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer’s Disease in Taiwan

Full copyright for enhanced digital features is owned by the authors. Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides</p

Comparison of mtDNA△Ct between normal controls and MDD patients.

<p>Comparison of mtDNA△Ct between normal controls and MDD patients.</p

Comparison of mtDNA copy number/per cell between normal controls and MDD patients.

<p>Comparison of mtDNA copy number/per cell between normal controls and MDD patients.</p

Generalized linear model to identify independent clinical variables associated with copy number and mtDNA∆Ct.

<p>TCA: tricyclic antidepressant.</p><p>SSRI: selective serotonin reuptake inhibitor.</p><p>SNRI: selective serotonin-norepinephrine inhibitor.</p><p>NaSSA: noradrenergic and specific serotonergic antidepressant.</p><p>BZDs: benzodiazepines.</p><p>Generalized linear model to identify independent clinical variables associated with copy number and mtDNA∆Ct.</p

The results of SERT and PPVT-R obtained from total participants and subgroups A and B.

<p>The statistical differences (<i>p</i> value) between groups A and B were demonstrated.</p

Relationship between the correct percentage in SERT and the PTA average on the better ear.

<p>The scatter plot with linear regression prediction line of 95% confidence interval of correct percentage in SERT and the independent variables (i.e.PTA on the better ear, in dB HL).</p